L'article souligne que les épidémies de choléra en Syrie et au Liban menacent gravement la santé et la survie des enfants. L'UNICEF alerte sur l'augmentation rapide des cas, exacerbée par des infrastructures d'eau et d'assainissement défaillantes, ainsi que par des systèmes de santé fragilis...és. L'organisation appelle à une action urgente pour améliorer l'accès à l'eau potable, renforcer les services de santé et mener des campagnes de vaccination afin de protéger les enfants contre cette maladie potentiellement mortelle.
more
The UNHCR Cholera Response Plan (October 2022 – March 2023) outlines efforts to combat the cholera outbreak in Lebanon, which was declared in October 2022. The plan, led by the Ministry of Public Health with support from UNHCR, WHO, UNICEF, and NGOs, focuses on prevention, response, and surveillan...ce. Key actions include oral cholera vaccination campaigns, rapid diagnostics, strengthening healthcare facilities, and improving hygiene and sanitation in high-risk refugee settlements and collective shelters. The response also emphasizes risk communication and community engagement to raise awareness and ensure early detection. The plan targets 120,000 individuals and requires $8.5 million in funding to provide life-saving support and containment measures.
more
La fièvre jaune est endémique dans plusieurs pays d'Amérique latine. Afin d'aider les décideurs à hiérarchiser les actions de prévention contre cette maladie, l'Organisation panaméricaine de la santé présente ces profils de pays avec une sélection concise et complète de données provenan...t des pays endémiques. Chaque profil fournit une analyse de la situation actuelle du pays, des facteurs écologiques et climatiques associés à la maladie, de la distribution et de l'incidence des vecteurs, ainsi que des principales activités des arbovirus. Il comprend également une perspective historique de l'épidémiologie et un résumé de la situation de la vaccination contre la maladie dans le pays.
more
Geneva, 22 May 2023 – Gavi, the Vaccine Alliance today published a roadmap* outlining critical actions needed to ensure supply of oral cholera vaccine (OCV) is able to meet growing demand from countries. Released against a backdrop of a recent wave of cholera outbreaks around the world, the roadma...p forecasts the short-, mid- and long-term outlook for global cholera vaccine supply. Developed in consultation with a range of key Alliance partners, including WHO, UNICEF, the Global Taskforce for Cholera Control (GTFCC), and the Bill and Melinda Gates Foundation (BMGF), it describes how these organizations, manufacturers and countries can work together towards ensuring global OCV supply can support largescale preventive vaccination by 2026.
more
La vidéo "Choléra - Questions & Réponses" de l'Organisation Mondiale de la Santé (OMS) explique les aspects essentiels du choléra, une maladie diarrhéique aiguë causée par l'ingestion d'eau ou d'aliments contaminés par la bactérie Vibrio cholerae. Elle met en avant les principaux symptôme...s, notamment une diarrhée aqueuse sévère, des vomissements et une déshydratation rapide, pouvant être mortelle sans traitement adéquat. La transmission se fait principalement par l’eau insalubre et les mauvaises conditions sanitaires. Pour prévenir la maladie, il est essentiel d'avoir accès à de l'eau potable, d'améliorer l'hygiène et l'assainissement, et d'utiliser la vaccination dans les zones à haut risque. En cas d'infection, la réhydratation orale ou intraveineuse est le traitement principal, tandis que les antibiotiques sont parfois administrés dans les cas graves. La vidéo insiste sur l'importance d'une intervention rapide et de mesures préventives pour limiter la propagation du choléra et protéger les populations à risque.
more
The video "Cholera - Questions & Answers" by the World Health Organization (WHO) explains the essential aspects of cholera, an acute diarrheal disease caused by ingesting water or food contaminated with the Vibrio cholerae bacterium. It highlights the main symptoms, including severe watery diarrhea,... vomiting, and rapid dehydration, which can be fatal without proper treatment. Transmission occurs primarily through unsafe water and poor sanitation conditions. To prevent the disease, it is crucial to have access to clean drinking water, improve hygiene and sanitation, and use vaccination in high-risk areas. In case of infection, oral or intravenous rehydration is the primary treatment, while antibiotics are sometimes administered in severe cases. The video emphasizes the importance of rapid intervention and preventive measures to limit the spread of cholera and protect at-risk populations.
more
Neonatal tetanus (NT), a severe newborn illness from the toxigenic strains of Clostridium tetani, persists in middle- and low-income countries due to non-sterile childbirth practices. Unlike smallpox and polio, tetanus cannot be eradicated: Clostridium tetani spores exist in the environment, and ani...mal reservoirs. However, elimination as a public health issue is achievable through widespread tetanus vaccination, clean deliveries, and proper umbilical cord care. The goal of eliminating maternal and neonatal tetanus (MNT) as a public health problem is considered met when all municipalities in a country have an annual incidence rate of NT of less than 1 case per 1000 live births. The Region of the Americas achieved the maternal and neonatal tetanus elimination (MNTE) target in 2017 when elimination was validated in the Republic of Haiti. Yet maintaining this progress requires continued efforts. High vaccination coverage, booster doses in countries lacking them, hygienic practices, and strong maternal and child health services are key. The Pan American Health Organization’s (PAHO) integrated maternal and neonatal immunization platform further strengthens this fight against early childhood diseases.
more
Response to the Periodic EpidemicThe document "Zanzibar's Victory Against Cholera Epidemic" details the successful efforts taken by Zanzibar to control and eliminate cholera outbreaks. It highlights the strategies implemented, including improved water and sanitation infrastructure, public health cam...paigns, vaccination programs, and rapid response measures. The report emphasizes community engagement, government commitment, and international partnerships as key factors in combating the disease. Zanzibar's experience serves as a model for other regions facing similar public health challenges, demonstrating that sustained efforts in hygiene, disease surveillance, and emergency preparedness can effectively control cholera epidemics.
more
The document is a comprehensive practical guide for managing cholera epidemics. It includes detailed instructions on outbreak investigation, control measures, case management, and the organization of treatment facilities. It emphasizes strategies such as rehydration therapy, water sanitation, hygien...e promotion, and vaccination to prevent the spread of cholera. The guide serves as a resource for healthcare professionals, logisticians, and public health officials to respond effectively to cholera outbreaks.
more
The document is a comprehensive practical guide for managing cholera epidemics. It includes detailed instructions on outbreak investigation, control measures, case management, and the organization of treatment facilities. It emphasizes strategies such as rehydration therapy, water sanitation, hygien...e promotion, and vaccination to prevent the spread of cholera. The guide serves as a resource for healthcare professionals, logisticians, and public health officials to respond effectively to cholera outbreaks.
more
Cervical cancer is the second most common cancer among women worldwide and causes a significant number of deaths in the South-East Asia Region. Nearly 200 000 new cases of cervical cancer occurred in SEA Region Member States in 2008, giving an incidence of almost 25 per 100... 000 and a mortality rate of almost 14 per 100 000. Cervical cancer can be prevented by early screening and vaccination. However, due to poor access to screening and treatment services, the vast majority of these deaths occur in women from nine Member States of the South-East Asia Region which account for more than one third of the global burden of cervical cancer.
more
This module is part of the WHO series The Immunological Basis for Immunization, which was initially developed in 1993 as a set of eight modules, comprising one module on general immunology and seven modules each devoted to one of the vaccines recommended for the Expanded Programme on Immunization, i....e. vaccines against diphtheria, measles, pertussis, polio, tetanus, tuberculosis and yellow fever. Since then, this series has been updated and extended to include other vaccines of international importance. The main purpose of the modules is to provide national immunization managers and vaccination professionals with an overview of the scientific basis of vaccination against a range of important infectious diseases. The modules developed since 1993 continue to be vaccine-specific, reflecting the biological differences in immune responses to the individual pathogens and the differing strategies employed to create the best possible level of protection that can be provided by vaccination. The modules also serve as a record of the immunological basis for the WHO recommendations on vaccine use, published in the WHO vaccine position papers.*
more
Over 18 months into the pandemic, WHO continues to conductglobal surveillance of COVID-19as part of activities on preparedness, readiness and response activities. The need for global surveillance of COVID-19 is greater than ever, asthe implementation of vaccination campaigns and the appearance of va...riants are prone to impact the course of the epidemic, as transmission patterns evolve. Timely and complete surveillance data are key to monitoring these changes.
Features include stratification by age and sex, trends over time, case fatality ratios by age, testing, hospitalization, and data on health workers –all visible at country and regional levels. The dashboard provides the ability for users to conduct further analyses by country and selected time period.
more
The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological
situation of the COVID-19 pandemic as of 21 January 2022 – at a time when the Omicron VOC had been identified in 171
countries across all six WHO Regions and was rapidly re...placing Delta worldwide – was considered Omicron has a substantial growth advantage, higher secondary attack rates and a higher observed reproduction number than Delta.
There is now significant evidence that immune evasion contributes to the rapid spread of Omicron. Other factors may be a shorter
serial interval (by about 0.8 to 1.2 days compared to Delta) and potential increased intrinsic transmission fitness . There is
growing evidence that with Omicron, there is lower vaccine effectiveness (VE) against infection and symptomatic disease soon after vaccination compared to Delta. There is also evidence of accelerated waning of VE over time of the primary series against infection and symptomatic disease for the studied vaccines. Further studies are required to better understand the drivers of transmission and declining incidence in various settings. These factors include the intrinsic transmission fitness properties of the virus, degree of immune evasion, vaccination coverage and level of vaccine-derived and post-infection immunity, levels of social mixing and degree of application of public health and social measures (PHSM).
more
Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Covid-19 Working Group webpage. This guidance should be considered along with the broader COVID-...19 policy advice to WHO member states and in particular the advice on how to reach the COVID-19 vaccination targets.
more
Le document fournit des messages éducatifs et des conseils pratiques pour prévenir et gérer la diarrhée, en particulier chez les enfants. Il met l'accent sur les pratiques d'hygiène telles que le lavage des mains adéquat, l'utilisation de latrines et la manipulation sûre des aliments. Il soul...igne également l'importance de l'allaitement maternel, d'une alimentation équilibrée, de la vaccination et de l'utilisation de solutions de réhydratation orale (SRO) et de zinc pour traiter la déshydratation causée par la diarrhée. Développé en collaboration avec les programmes de Save the Children en République démocratique du Congo, le matériel intègre l'éducation à la santé dans les écoles et les communautés, en encourageant les enfants à agir comme agents de changement pour promouvoir les pratiques d'hygiène et de santé.
more
L’orthopoxvirus simien ou virus de la variole du singe (MPXV), est un virus à ADN double brin qui appartient au genre Orthopoxvirus de la famille
des Poxviridés. Les poxvirus causent des maladies chez l’espèce humaine et beaucoup d’autres animaux ; l’infection se manifeste généralement... par la formation de lésions, de nodules cutanés ou d’une éruption cutanée disséminée. Les autres espèces d’orthopoxvirus (OPXV) pathogènes pour l’être humain comprennent le virus de la variole bovine et le virus variolique (responsable de la variole, qui a été éradiquée). Le virus de la vaccine est également un OPXV qui a été utilisé pour la vaccination humaine, et a été un outil essentiel pour l’éradication de la variole, obtenue en 1980. Le MPXV doit son nom au fait qu’il a été identifié pour la première fois chez le singe. Le MPXV se retrouve principalement chez les rongeurs, mais son réservoir reste indéterminé. Il existe deux clades connus du MPXV, l’un endémique en Afrique de l’Ouest, et l’autre dans la région du bassin du Congo.
more
1.0 PURPOSE
To define the procedure for the conduct of in-person meetings in both healthcare and community settings in response to COVID-19 and with respect to Public Health and Social Measures (PHSMs) to reduce the risk of disease transmission. A general risk assessment must be conducted to inform... context specific recommendations.
2.0 SCOPE
The procedure in this document is applicable to all meetings that require convening people
together physically.
3.0 SAFETY AND HYGIENE PROCEDURE
Before entry into the meeting room/venue:
• Presentation of evidence for complete doses of COVID-19 vaccination (depending on COVID-19 vaccine taken) or negative COVID-19 PCR test done within the last 72 hours, or where applicable proof of daily negative RDT result. The Africa Union Trusted Travel platform, with technical support from the PanaBIOS Consortium has implemented an online system that allows Airlines and Port Health services to authenticate and verify traveler’s COVID-19 results certificates in line with international standards, across Africa and beyond.
• Hand hygiene stations should be available at the points of entry.
• All participants must wear a well fitted mask that covers the nose and mouth. Medical masks should be provided all meeting participants.
more
Main Points
The delivery of humanitarian assistance is expected to slow down significantly over the next seven to ten days in anticipation of the electoral process and limited availability of transport and security assets.
The percentage of extremely food-insecure people who have recei...ved food assistance increased to 65 per cent, as 520,000 people of the targeted 806,000 have now been reached.
Health partners have expressed concern over growing evidence of a spike in cases of severe acute malnutrition in hard-to-reach areas in the Sud region.
Cholera response partners are optimistic that the vaccination campaign of 8 to 15 November will contribute to reducing transmission in Sud and rand’Anse and the risk of a future outbreak
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more